DIRS.INFO The most relevant business & tech news

Globally, the figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International said. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. read morePatient advocacy groups hailed the news of positive lecanemab trial results. Micro hemorrhages in the brain occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.

REUTERS/Dado Ruvic/IllustrationBOSTON, Sept 26 (Reuters) - Biogen Inc (BIIB.O) has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs, the U.S. Department of Justice said on Monday. The settlement resolves a long-running whistleblower lawsuit in Boston federal court that a former employee pursued on the government's behalf. Biogen in July disclosed it reached a potential settlement, which was subject to government approval. As a reward, Bawduniak will receive $250 million of the federal government's $843.8 million share of the settlement. Another $56.2 million will be paid to 15 states, the Justice Department said.

☆ UBS upgrades Eli Lilly to buy, says it's developing possibly ‘the biggest drug ever’
▼ + stars: | 2022-09-22 | by ( Carmen Reinicke | ) www.cnbc.com time to read: +2 min

UBS is moving off the sidelines and saying now is the time to snap up Eli Lilly citing a key weight loss drug. The rating change comes after mounjaro, or tirzepatide, a key weight loss drug, showed promise in a random study called Surmount-1 and was approved for use in patients with type 2 diabetes. Weight loss drug could be biggest ever The weight loss drug could be the "biggest drug ever" with estimated peak annual sales of $25 billion, according to the firm's estimate. Several drug companies have weight loss drugs in development , making it a possible big driver of the stocks in coming years. In the near-term, there is downside risk if the company's weight loss drug is not able to file for use in obesity, the note said.

☆ Biogen says ALS drug shows clinical benefit in new data analysis
▼ + stars: | 2022-09-21 | by ( Mrinalika Roy | ) www.reuters.com time to read: +2 min

The Biogen drug, tofersen, is currently under priority review by the U.S. Food and Drug Administration with an approval decision expected by Jan. 25. Biogen last October had said the drug missed the main goal of the late-stage study, failing to show statistically significant improvement in the functional status of patients with fast-progressing ALS at six months. Biogen is seeking approval of tofersen for ALS patients with mutations in a specific gene that leads to accumulation of toxic levels of a protein called SOD1. Most side effects in both the late-stage study and the follow-on portion were mild to moderate, including headache and back pain, the company said. Nearly 7% of patients who received tofersen experienced serious neurological events, including spinal cord inflammation and swelling of the optic nerve.

☆ 4 takeaways from the Investing Club’s ‘Morning Meeting’ on Tuesday
▼ + stars: | 2022-09-06 | by ( Krystal Hur | ) www.cnbc.com time to read: +4 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Our trades on DVN and CRM We sold 100 shares of recently rallying Devon Energy (DVN) and bought 50 shares of beaten-up Salesforce (CRM) on Tuesday morning. Watching these bullpen stocks Some of our Bullpen names that we're keeping tabs on for buying opportunities are Palo Alto Networks (PANW), PepsiCo (PEP) and Estee Lauder (EL). (Jim Cramer's Charitable Trust is long DVN, HON, CRM. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Search resuls for: "BIIB"

5 mentions found